Macrolides in cystic fibrosis: Is there a role?

American Journal of Respiratory Medicine

Volumn 1, Issue 4, 2002, Pages 235-241

  Wolter, Joanne M ^a   Seeney, Sharon L ^a   McCormack, Joseph G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CELL SURFACE PROTEIN; CLARITHROMYCIN; ERYTHROMYCIN; GLYCOPROTEIN P; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MACROLIDE; ROKITAMYCIN; ROXITHROMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BRONCHIOLITIS; CHILD; CONCENTRATION (PARAMETERS); CYSTIC FIBROSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; SPUTUM ANALYSIS;

AZITHROMYCIN; CYSTIC FIBROSIS; HUMANS; MACROLIDES; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY FUNCTION TESTS;

EID: 0042887638     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256614     Document Type: Review

References (60)

1. Doull IJ. Recent advances in cystic fibrosis. Arch Dis Child 2001; 85: 62-6
2. Thompson AB, Smits WL, Fick RB. Immunomodulatory therapies for cystic fibrosis. Semin Respir Infect 1992; 7 (3): 218-26
3. Lai H-C, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone therapy in children with cystic fibrosis. N Engl J Med 2000; 342: 851-9
4. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-54
5. Koch C, McKenzie SG, Kaplowitz H, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the epidemiologic registry of cystic fibrosis (ERCF). Pediatr Pulmonol 1997; 24: 147-54
6. Konstan MW. Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med 1998; 19: 505-13
7. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis. Chest 1999; 115: 1053-8
8. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998; 4: 116-21
9. Tanimoto H. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother 1991; 44: 94-8
10. Keicho N, Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy. Am J Respir Med 2002; 1 (2): 119-31
11. Ichikawa Y, Ninomiya H, Koga H, et al. Erythomycin reduces neutrophils and neutriphil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis. Am Rev Respir Dis 1992; 146: 196-203
12. Kobayashi H, Takeda H, Sakayori S, et al. Study on azithromycin in treatment of diffuse panbronchiolitis [abstract 6]. Kansenshogaku Zasshi 1995; 69: 711-22
13. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995; 23: S10-4
14. Kawamura-Sato K, Iinuma Y, Hasegawa T, et al. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000; 44: 2869-72
15. Mizukane R, Hirakata Y, Kaku M, et al. Comparative in vitro exoenzyme suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38 (3): 528-33
16. Molinari G, Guzman CA, Pesce A, et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31: 681-8
17. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections. J Antimicrob Chemother 1997; 40: 153-5
18. Tateda K, Ishi Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependant bacteriocidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40 (10): 2271-5
19. Sakata K, Yajima H, Tanaka K, et al. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Resp Dis 1993; 148: 1061-5
20. Ichimiya T, Takeoka K, Hiramatsu K, et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42: 186-91
21. Baumann U, Fischer JJ, Gudowius P, et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2000; 29: 7-11
22. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001 Jun; 31 (6): 464-73
23. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429 (1-3): 209-29
24. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 41 Suppl. B: 37-46
25. Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13: 3-8
26. Villagrasa V, Berto L, Cortijo J, et al. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen Pharmacol 1997; 29 (4): 605-9
27. Sugihara E. Effect of macrolide antibiotics on neutrophil function in human peripheral blood [abstract 4]. Kansenshogaku Zasshi 1997; 71: 359-36
28. Okubo Y. Macrolides reduce the expression of surface mac-1 molecule on neutrophils. Kurume Med J 1997; 44: 115-23
29. Richman-Eisenstat JY, Jorens PG, Hebert CA, et al. Interleukin-8: an important chemoattractant in sputum of patients with chronic airways disease. Am J Physiol 1993; 264: L413-8
30. Wolter JM, Rodwell RL, Bowler SD, et al. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diag Lab Immunol 1999; 6 (2): 260-5
31. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-8
32. Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63 (1): 42-8
33. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995; 210 (3): 781-6
34. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266-71
35. Desaki M, Takizawa H, Ohtosh T, et al. Erythromycin suppresses nuclear factor-kappa B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Common 2000; 267 (1): 124-8
36. Abe S, Nakomura H, Inove S, et al. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000; 22 (1): 51-60
37. Elborn JS, Cordon SM, Parker D, et al. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 1993; 87: 603-7
38. Greally P, Hussein MJ, Cook AJ, et al. Sputum tumor necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389-92
39. Kronborg G, Hansen MB, Svenson M, et al. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol 1993; 15: 292-7
40. Iino Y, Toriyama M, Natori Y, et al. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol 1992; 101: 16-20
41. Bell SC, Wolter JM, Seeney SL, et al. Azithromycin (AZM) reduces TNF-α release from lipopolysaccharide (LPS)-stimulated mononuclear cells (PBMC) in cystic fibrosis (CF) [abstract]. Pediatr Pulmonol 2000; 20: 260
42. Neu HC. Clinical microbiology of azithromycin. Am J Med 1991; 91: S12-8
43. Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid in individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478-84
44. Meyer KC, Lewandowski JR, Zimmerman JJ, et al. Human neutrophil elastase and elastase/alpha-1-antiprotease complex in cystic fibrosis. Am Rev Respir Dis 1991; 144: 580-5
45. Hollsing AE, Lantz B, Bergstrom K, et al. Granulocyte elastase-alpha-1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections. J Pediatr 1987; 111: 206-11
46. Ordonez CL, Stulbarg M, Grudland H, et al. Effect of clarithromcin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32: 29-37
47. Altschuler EL. Azithromycin, the multidrug-resistant protein and cystic fibrosis [letter]. Lancet 1998; 351: 1286
48. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis [letter]. Lancet 1998; 351: 420
49. Wolter JM, Seeney S, Bell S, et al. Effect of longterm treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57 (3): 212-6
50. Dean TP, Dai Y, Shute JK, et al. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, and sera of children with cystic fibrosis. Pediatr Res 1993; 34: 159-61
51. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997 Feb; 41 (2): 161-5
52. Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]. Pediatr Pulmonol 1999; 28 Suppl. 19: 263
53. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis (Cochrane Review). In: The Cochrane Database of Systematic Reviews. Available from The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2001
54. Anstead MI, Kuhn RJ, Halsey S, et al. Prolonged beneficial effect of chronic azithromycin therapy on lung function in cystic fibrosis. Pediatr Pulmonol 2000; Suppl. 20: 244
55. Equi A, Bush A, Alton EW, et al. A prospective, double-bind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatr Pulmonol 2001; Suppl. 22: 307
56. Oldfield EC, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomised, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998; 26: 611-9
57. Maeda K, Mikasa K, Konishi M, et al. Acute exacerbations due to Streptococcus pneumoniae in chronic respiratory infections during long-term macrolide therapy. Kansenshogaku Zasshi 2001 Oct; 75 (10): 846-50
58. Govan JR, Hughes JE, Vandamme P. Burkholderia cepacia: medical; taxonomic and ecological issues. J Med Microbiol 1996; 45: 395-407
59. Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994; 49: 115-20
60. Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996; 51: 29-33